TCHL – a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, rastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis

Background: The docetaxel (T), carboplatin (C) and trastuzumab (H) regimen has been used in the (neo-) adjuvant treatment of HER2+ early stage breast cancer (ESBC). Lapatinib (L) a small molecule HER2 antagonist produces clinical responses following H failure. Methods: We randomly assigned 88 patie...

Full description

Saved in:

Bibliographic Details
Main Authors:	John Crown, Alex J. Eustace, Denis M. Collins, Maccon Keane, Linda Coate, John Kennedy, Seamus O'Reilly, Catherine Kelly, Miriam O'Connor, Michael Martin, Conleth Murphy, Karen Duffy, Janice Walshe, Giuseppe Gullo, Thamir Mahgoub, Alberto Alvarez-Iglesias, Imelda Parker, Vicky Donachie, Ausra Teiserskiene, Stephen F. Madden, Brian Moulton, Norma O'Donovan, Bryan T. Hennessy
Format:	Article
Language:	English
Published:	Medical Journals Sweden 2025-06-01
Series:	Acta Oncologica
Subjects:	HER2-positive breast cancer neoadjuvant therapy Trastuzumab lapatinib tyrosine kinase inhibitors
Online Access:	https://medicaljournalssweden.se/actaoncologica/article/view/43143
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

TCHL – a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, rastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis

Similar Items